Interleukin-18, interferon-gamma, IP-10, and Mig expression in Epstein-Barr virus-induced infectious mononucleosis and posttransplant lymphoproliferative disease.

[1]  J. Friedland,et al.  Respiratory Syncytial Virus-Induced RANTES Production from Human Bronchial Epithelial Cells Is Dependent on Nuclear Factor-κB Nuclear Binding and Is Inhibited by Adenovirus-Mediated Expression of Inhibitor of κBα , 1998, The Journal of Immunology.

[2]  G. Trinchieri,et al.  Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. , 1998, The Journal of clinical investigation.

[3]  J. Torre-Cisneros,et al.  Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: the role of cytomegalovirus disease. , 1997, The Journal of infectious diseases.

[4]  Hiroshi Sato,et al.  CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. , 1997, Science.

[5]  W. Wilson,et al.  The role of Mig, the monokine induced by interferon-gamma, and IP-10, the interferon-gamma-inducible protein-10, in tissue necrosis and vascular damage associated with Epstein-Barr virus-positive lymphoproliferative disease. , 1997, Blood.

[6]  R. Kastelein,et al.  IGIF Does Not Drive Th1 Development but Synergizes with IL-12 for Interferon-γ Production and Activates IRAK and NFκB , 1997 .

[7]  H. Heslop,et al.  Adoptive cellular immunotherapy for EBV lymphoproliferative diseases , 1997 .

[8]  P. Beatty,et al.  Involvement of IL-10 in the autonomous growth of EBV-transformed B cell lines. , 1997, Journal of immunology.

[9]  J. Teruya-Feldstein,et al.  Mig, the monokine induced by interferon-γ, promotes tumor necrosis in vivo , 1997 .

[10]  H. Okamura,et al.  Interleukin 18 together with interleukin 12 inhibits IgE production by induction of interferon-gamma production from activated B cells. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[11]  J. Farber.  Mig and IP‐10: CXC chemokines that target lymphocytes , 1997, Journal of leukocyte biology.

[12]  N. Harris,et al.  Posttransplant lymphoproliferative disorders: summary of Society for Hematopathology Workshop. , 1997, Seminars in diagnostic pathology.

[13]  T. Tanimoto,et al.  In vivo antitumor effects of murine interferon- γ -inducing factor/interleukin-18 in mice bearing syngeneic Meth A sarcoma malignant ascites , 1997, Cancer Immunology, Immunotherapy.

[14]  Y. Oh-Ichitagawa.  Interleukin 18 together with interleukin 12 inhibits IgE production by induction of interferon-g production from activated B cells (helminthycytokine) , 1997 .

[15]  H. Heslop,et al.  Adoptive cellular immunotherapy for EBV lymphoproliferative disease. , 1997, Immunological reviews.

[16]  L. Koniaris,et al.  Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[17]  A. Rickinson,et al.  Cytotoxic T lymphocyte responses to Epstein-Barr virus. , 1996, Current opinion in immunology.

[18]  T. Tanimoto,et al.  Interferon‐γ‐inducing factor enhances T helper 1 cytokine production by stimulated human T cells: synergism with interleukin‐12 for interferon‐γ production , 1996 .

[19]  H. Okamura,et al.  Cloning of the cDNA for human IFN-gamma-inducing factor, expression in Escherichia coli, and studies on the biologic activities of the protein. , 1996, Journal of immunology.

[20]  K. Bendtzen,et al.  Interleukin-10 and Epstein-Barr virus-induced posttransplant lymphoproliferative disorder. , 1996, Transplantation.

[21]  J. Bavaria,et al.  Analysis of Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after lung transplantation. , 1996, Surgery.

[22]  Malcolm K. Brenner,et al.  Long–term restoration of immunity against Epstein–Barr virus infection by adoptive transfer of gene–modified virus–specific T lymphocytes , 1996, Nature Medicine.

[23]  G. Heller,et al.  The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation. , 1996, Blood.

[24]  E. Jaffe,et al.  Epstein-Barr virus latent membrane protein-1 oncogene deletions: correlations with malignancy in Epstein-Barr virus--associated lymphoproliferative disorders and malignant lymphomas. , 1996, Blood.

[25]  J. Stewart,et al.  The Epstein-Barr virus encoded cytokine viral interleukin-10 enhances transformation of human B lymphocytes. , 1995, Oncogene.

[26]  H. Okamura,et al.  Cloning of a new cytokine that induces IFN-γ production by T cells , 1995, Nature.

[27]  E. Raymond,et al.  Epstein‐Barr virus‐related localized hepatic lymphoproliferative disorders after liver transplantation , 1995, Cancer.

[28]  B. Premack,et al.  Activation of dual T cell signaling pathways by the chemokine RANTES. , 1995, Science.

[29]  N. Harris,et al.  Posttransplantation lymphoproliferative disorders in solid organ recipients are predominantly aggressive tumors of host origin. , 1995, American journal of clinical pathology.

[30]  G. Tosato,et al.  Human and viral interleukin-10 in acute Epstein-Barr virus-induced infectious mononucleosis. , 1995, The Journal of infectious diseases.

[31]  M. Pawlita,et al.  Suppression of Burkitt's lymphoma tumorigenicity in nude mice by co‐inoculation of EBV‐immortalized lymphoblastoid cells , 1995, International journal of cancer.

[32]  R. Braylan,et al.  Optimal primer selection for clonality assessment by polymerase chain reaction analysis: II. Follicular lymphomas. , 1994, Human pathology.

[33]  D. Dunn,et al.  Clinical characteristics of post-transplant lymphoproliferative disorders. , 1994, The American journal of medicine.

[34]  M. Shin,et al.  Definition of a lipopolysaccharide-responsive element in the 5'-flanking regions of MuRantes and crg-2 , 1994, Molecular and cellular biology.

[35]  M. Ladanyi,et al.  Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. , 1994, The New England journal of medicine.

[36]  I. Ernberg,et al.  Epstein-Barr virus: adaptation to a life within the immune system. , 1994, Trends in Microbiology.

[37]  K. Bhatia,et al.  Regression of experimental Burkitt's lymphoma induced by Epstein-Barr virus-immortalized human B cells. , 1994, Blood.

[38]  R. Michler,et al.  Management of lymphoproliferative disorders after cardiac transplantation. , 1993, The Annals of thoracic surgery.

[39]  J. Preiksaitis,et al.  POST‐TRANSPLANT LYMPHOPROLIFERATIVE DISORDER IN RENAL ALLOGRAFT RECIPIENTS: CLINICAL EXPERIENCE AND RISK FACTOR ANALYSIS IN A SINGLE CENTER , 1993, Transplantation.

[40]  S. McColl,et al.  Expression of the cytokine RANTES in human rheumatoid synovial fibroblasts. Differential regulation of RANTES and interleukin-8 genes by inflammatory cytokines. , 1993, The Journal of biological chemistry.

[41]  J. Meier,et al.  NIH conference. Epstein-Barr virus infections: biology, pathogenesis, and management. , 1993, Annals of internal medicine.

[42]  J. Meier,et al.  Epstein-Barr Virus Infections: Biology, Pathogenesis, and Management , 1993, Annals of Internal Medicine.

[43]  G. Trinchieri,et al.  Mechanisms of IFN-gamma induction by natural killer cell stimulatory factor (NKSF/IL-12). Role of transcription and mRNA stability in the synergistic interaction between NKSF and IL-2. , 1992, Journal of immunology.

[44]  R. Fisher,et al.  Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. , 1990, The New England journal of medicine.

[45]  N. Harris,et al.  Lymphoproliferative disorders and hematologic malignancies following organ transplantation. , 1989, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[46]  G. Heller,et al.  Immune reconstitution following bone marrow transplantation: comparison of recipients of T-cell depleted marrow with recipients of conventional marrow grafts. , 1989, Blood.

[47]  J. Locker,et al.  The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. , 1988, The American journal of pathology.

[48]  K. Welte,et al.  Interleukin 2-activated killer cells in patients following transplants of soybean lectin-separated and E rosette-depleted bone marrow. , 1987, Blood.

[49]  S. Orkin,et al.  Phenotype of recovering lymphoid cell populations after marrow transplantation , 1985, The Journal of experimental medicine.

[50]  T. Starzl,et al.  REVERSIBILITY OF LYMPHOMAS AND LYMPHOPROLIFERATIVE LESIONS DEVELOPING UNDER CYCLOSPORIN-STEROID THERAPY , 1984, The Lancet.